Opus Genetics CFO logs tax-related share sale

Opus Genetics, Inc. Chief Financial Officer Robert E. Gagnon reported an automatic sale of 7,842 shares of Common Stock on April 23, 2026.

Rhea-AI Filing Summary

Opus Genetics, Inc. Chief Financial Officer Robert E. Gagnon reported an automatic sale of 7,842 shares of Common Stock on April 23, 2026. The sale was executed at a weighted average price of $5.1846 per share to satisfy tax withholding obligations arising from the vesting and settlement of a restricted stock unit award, and was not a discretionary trade. After this transaction, Gagnon directly holds 592,158 shares of Opus Genetics common stock. The shares were sold in multiple trades at prices ranging from $5.1828 to $5.1901 per share.

Insider Trade Summary

Net Seller: 7,842 shares

Net Sell 1 txn

Insider Gagnon Robert E.

Role Chief Financial Officer

Sold 7,842 shs ($41K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,842	$5.1846	$41K

Holdings After Transaction: Common Stock — 592,158 shares (Direct)

Footnotes (2)

1. F1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.
2. F2. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.1828 to $5.1901, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 7,842 shares Weighted average sale price: $5.1846 per share Post-transaction holdings: 592,158 shares +2 more

5 metrics

Shares sold 7,842 shares Automatic sale on April 23, 2026

Weighted average sale price $5.1846 per share Common Stock sale to cover tax withholding

Post-transaction holdings 592,158 shares Common Stock held directly after sale

Sale price range $5.1828–$5.1901 per share Multiple transactions on April 23, 2026

Net shares sold 7,842 shares Net sell direction in transaction summary

Key Terms

restricted stock units, tax withholding obligations, weighted average price, vesting and settlement event

4 terms

restricted stock units financial

"a vesting and settlement event from a restricted stock units award"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"required by the Company to satisfy tax withholding obligations that arose"

weighted average price financial

"The price in column 4 represents the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vesting and settlement event financial

"obligations that arose in connection with a vesting and settlement event"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Opus Genetics (IRD) report for CFO Robert Gagnon?

Opus Genetics reported that CFO Robert Gagnon had 7,842 common shares sold on his behalf. The sale satisfied tax withholding obligations from a restricted stock unit vesting event, rather than reflecting a discretionary open-market decision to reduce his investment.

How many Opus Genetics (IRD) shares were sold and at what price?

A total of 7,842 Opus Genetics common shares were sold at a weighted average price of $5.1846 per share. The transactions occurred within a narrow range, from $5.1828 to $5.1901 per share, according to the Form 4 footnote disclosure.

Why were Opus Genetics (IRD) shares sold for CFO Robert Gagnon?

The shares were sold automatically to cover tax withholding obligations from a restricted stock unit vesting and settlement event. The filing states this sale was required by the company and does not represent a discretionary trading decision by CFO Robert Gagnon.

How many Opus Genetics (IRD) shares does CFO Robert Gagnon hold after the sale?

Following the tax-related sale, CFO Robert Gagnon directly holds 592,158 shares of Opus Genetics common stock. This post-transaction balance in the Form 4 helps investors understand that the disposed 7,842 shares are a small portion of his overall holdings.

Was the Opus Genetics (IRD) insider sale part of a trading plan or a routine tax event?

The Form 4 states the sale was automatic and required by the company to satisfy tax withholding obligations tied to restricted stock unit vesting. It characterizes the transaction as non-discretionary, distinguishing it from a voluntary open-market trading decision by the insider.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gagnon Robert E.

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/23/2026		S(1)		7,842	D	$5.1846(2)	592,158	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

2. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.1828 to $5.1901, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Amy Rabourn, by Power of Attorney	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)